

## **Indoco's Top-line Grows By Over 13% Q-O-Q**

July 22, 2010

Indoco Remedies Limited, a global pharmaceutical company, has scored a growth of 13% to Rs. 1113.8 million from Rs. 983.4 million over same quarter last year. PAT for the quarter stood at Rs. 148.20 million. The Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on July 22, 2010 announced the first quarter un-audited results for the financial year 2010-11.

Commenting on the performance, Mr. Suresh G. Kare, Chairman & Managing Director said, "The global slowdown has portrayed many growth challenges and still there are many serious problems facing the economies around the world. A considerable introspection and realignment of business strategies is required for corporate India to continue the growth momentum. As far as the Pharma Industry is concerned, there are grounds for optimism in the forthcoming year. We wish to assure our investors that Indoco's performance in the Indian markets shows potential and our international business has shown good growth. Indoco's growth strategies are well placed to progressively pursue higher growth, for both domestic and international business."

### **HIGHLIGHTS:**

#### **For First Quarter ended June 2010 of FY 2010-11:**

**Net Sales at Rs. 1113.8 million**

**Net Profit at Rs. 148.2 million**

**EPS at Rs. 12.06**